Media stories about Versartis (NASDAQ:VSAR) have trended somewhat positive this week, according to Accern. The research firm ranks the sentiment of press coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Versartis earned a media sentiment score of 0.10 on Accern’s scale. Accern also gave media coverage about the biopharmaceutical company an impact score of 46.5321938493797 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

These are some of the headlines that may have impacted Accern Sentiment’s analysis:

Several equities research analysts recently issued reports on the company. BidaskClub cut Versartis from a “buy” rating to a “hold” rating in a research note on Wednesday, August 2nd. Zacks Investment Research cut Versartis from a “hold” rating to a “sell” rating in a research note on Wednesday, August 2nd. Canaccord Genuity set a $28.00 price target on Versartis and gave the company a “buy” rating in a research note on Friday, July 28th. Cantor Fitzgerald set a $34.00 target price on Versartis and gave the stock a “buy” rating in a research note on Thursday, July 27th. Finally, Piper Jaffray Companies set a $26.00 target price on Versartis and gave the stock a “buy” rating in a research note on Tuesday, June 27th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and seven have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $25.13.

Shares of Versartis (VSAR) traded up 0.28% on Monday, hitting $17.95. 236,407 shares of the stock traded hands. Versartis has a 52 week low of $9.05 and a 52 week high of $24.00. The stock has a 50-day moving average price of $17.66 and a 200 day moving average price of $17.90. The firm’s market cap is $633.92 million.

Versartis (NASDAQ:VSAR) last posted its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported ($1.04) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.84) by $0.20. Equities research analysts predict that Versartis will post ($3.29) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Versartis (VSAR) Getting Somewhat Favorable News Coverage, Report Shows” was originally published by Daily Political and is the sole property of of Daily Political. If you are reading this piece on another site, it was illegally stolen and reposted in violation of international copyright and trademark law. The legal version of this piece can be viewed at https://www.dailypolitical.com/2017/08/07/versartis-vsar-getting-somewhat-favorable-news-coverage-report-shows.html.

Versartis Company Profile

Versartis, Inc is an endocrine-focused biopharmaceutical company. The Company is engaged in developing a long-acting form of recombinant human growth hormone, somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company’s first indication for somavaratan is pediatric GHD.

Insider Buying and Selling by Quarter for Versartis (NASDAQ:VSAR)

Receive News & Ratings for Versartis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Versartis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.